Collage photo of Edgar Braendle and Amalya Sargsyan
Jul 25, 2025, 14:04
Edgar Braendle Shares Career Insights in Drug Development with Amalya Sargsyan – AVEO Oncology
AVEO Oncology shared a post on LinkedIn:
“Edgar Braendle, MD, PhD, Chief Medical Officer at AVEO Oncology, an LG Chem company, recently joined host Amalya Sargsyan, Medical Oncologist and Head of Research, on the OncoDaily podcast, sharing key insights throughout his career in drug development.
In the episode, Dr. Braendle reviews data from two Phase 3 trials for FOTIVDA (tivozanib) while also discussing AVEO’s pipeline agents ficlatuzumab (AV-299) and rilogrotug (AV-380). For more details, you can watch the full episode.”
More posts featuring AVEO Oncology.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 25, 2025, 22:02
Jul 25, 2025, 21:34
Jul 25, 2025, 21:01
Jul 25, 2025, 20:41
Jul 25, 2025, 20:07
Jul 25, 2025, 19:11
Jul 25, 2025, 17:20